SHH is a lipidated morphogen essential for embryonic patterning and development. Its primary function involves specifying cell fates along developmental axes: it induces ventral cell specification in the neural tube and somites 1, and orchestrates cerebellar development through signaling in germinal zones and Purkinje cells 2. SHH activates transcription via binding to PTCH1 receptor, which normally represses SMO signaling in the absence of SHH 3. In the brain, SHH operates within regulatory feedback loops involving GLI3 and BMP7 that modulate cortical neurogenesis 4. SHH also regulates gastric epithelial regeneration and differentiation in adults 5. Disruption of SHH signaling causes multiple human malformation syndromes affecting brain size, craniofacial morphology, and limb development; these phenotypes result from imbalances in GLI activator versus repressor forms 6. SHH pathway mutations underlie holoprosencephaly, polydactyly variants, and other skeletal-craniofacial malformations. Pathologically, aberrant SHH signaling drives medulloblastoma, the most common pediatric brain malignancy; SHH-subtype tumors depend on pathway activation and represent ~30% of cases 78. Recent studies demonstrate therapeutic potential through targeting pathway effectors like SALL4 in SHH-dependent cancers, offering clinical opportunities beyond current limited options.